Given a hepatitis C virus RNA viral load of 2,870,000 IU/mL (6.46 log10) on quantitative real-time PCR, what are the appropriate next steps in management?

Next Steps for HCV RNA 2,870,000 IU/mL (6.46 log10)

You need to determine the HCV genotype and assess liver fibrosis severity before initiating treatment, as these two factors will dictate your specific treatment regimen and duration.

Immediate Diagnostic Workup

1. HCV Genotype Testing (Essential)

• Genotype determination is mandatory before treatment 1
• This viral load (2.87 million IU/mL) is considered high, which historically influenced treatment duration in older interferon-based regimens 2
• However, with modern direct-acting antivirals (DAAs), treatment should NOT be withheld based on viral load alone 2

2. Liver Fibrosis Assessment (Critical)

You must determine if cirrhosis is present using:

Non-invasive options (preferred):

• FIB-4 score calculation (age, AST, ALT, platelet count) 3
  • FIB-4 >3.25 suggests cirrhosis
  • This is the simplest initial screening tool
• Transient elastography (FibroScan) if available

  • 12.5 kPa indicates cirrhosis 1

• Clinical evidence: liver nodularity, splenomegaly on imaging, platelet count <150,000/mm³ 3

Liver biopsy is NOT required for treatment decisions in the modern era 3

3. Additional Baseline Testing

• Complete blood count, comprehensive metabolic panel
• HIV and HBsAg testing 3
• Pregnancy test if applicable
• Medication reconciliation for drug-drug interactions 3

Treatment Planning Based on Results

If Genotype 1 (Most Common):

Treatment-Naïve Without Cirrhosis:

• Sofosbuvir/ledipasvir for 12 weeks (can shorten to 8 weeks if HCV RNA <6 million IU/mL, which applies to this patient at 2.87 million) 1
• Alternative: Glecaprevir/pibrentasvir for 8 weeks 3
• Alternative: Sofosbuvir/velpatasvir for 12 weeks 3

Treatment-Naïve With Compensated Cirrhosis:

• Sofosbuvir/ledipasvir for 12 weeks without ribavirin 1
• Do NOT shorten to 8 weeks if cirrhosis present 1

If Genotype 2 or 3:

• Sofosbuvir/velpatasvir for 12 weeks 1
• Treatment duration is 12 weeks regardless of viral load for genotypes 2/3 2

If Genotype 4,5, or 6:

• Follow genotype 1 treatment algorithms 1

Key Clinical Pitfalls to Avoid

1. Do NOT delay treatment waiting for "lower viral load" - this is outdated thinking from the interferon era 2

2. Do NOT use interferon-based regimens - DAAs have >90% cure rates with minimal side effects and are the standard of care 1, 3

3. Do NOT skip genotype testing - while some pan-genotypic regimens exist, genotype still influences optimal treatment selection 1, 3

4. Do NOT assume no cirrhosis without assessment - treatment duration and regimen selection depend on cirrhosis status 1

5. Ensure complete medication review - DAAs have significant drug-drug interactions, particularly with proton pump inhibitors, anticonvulsants, and HIV medications 3

Monitoring During Treatment

For simplified treatment approach (if no cirrhosis, treatment-naïve):

• No routine laboratory monitoring required during treatment 3
• Monitor for hypoglycemia if diabetic
• Monitor INR if on warfarin
• Optional telehealth check-in for adherence support 3

Post-treatment:

• HCV RNA quantification at 12 weeks after completion to confirm sustained virological response (SVR = cure) 3
• Check hepatic function panel for transaminase normalization 3

Bottom Line Algorithm

1. Order genotype + FIB-4 calculation today
2. If FIB-4 ≤3.25 (no cirrhosis) + treatment-naïve: Start sofosbuvir/ledipasvir or glecaprevir/pibrentasvir after genotype results
3. If FIB-4 >3.25 (cirrhosis): Adjust treatment duration to 12 weeks minimum, avoid 8-week regimens
4. Confirm cure with HCV RNA at 12 weeks post-treatment

The high viral load (2.87 million IU/mL) does NOT negatively impact cure rates with modern DAAs - expect >95% SVR with appropriate regimen selection 1.